Bronchiectasis is a chronic inflammatory airway disease characterized by frequent exacerbations and neutrophilic inflammation. Dipeptidyl peptidase-1 (DPP-1) inhibitors block neutrophil serine protease activation and represent a promising therapeutic approach. This meta-analysis aimed to evaluate the efficacy and safety of DPP-1 inhibitors in adults with bronchiectasis.